Leap Therapeutics (LPTX) Stock Forecast & Price Target

$2.59 -0.11 (-4.07%)

(As of 11/20/2024 ET)

Leap Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
0

Buy
3

Based on 3 Wall Street analysts who have issued ratings for Leap Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for LPTX.

Consensus Price Target

$7.50
189.58% Upside

According to the 3 analysts' twelve-month price targets for Leap Therapeutics, the average price target is $7.50. The highest price target for LPTX is $9.00, while the lowest price target for LPTX is $5.50. The average price target represents a forecasted upside of 189.58% from the current price of $2.59.

Get the Latest News and Ratings for LPTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Leap Therapeutics and its competitors.

LPTX Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$7.50	$10.40	$10.40	$17.30
Forecasted Upside	189.58% Upside	242.11% Upside	282.35% Upside	504.90% Upside
Consensus Rating	Buy	Buy	Buy	Buy

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

LPTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LPTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Leap Therapeutics Stock vs. The Competition

Type	Leap Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	189.58% Upside	26,931.56% Upside	9.82% Upside
News Sentiment Rating	Positive News See Recent LPTX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	HC Wainwright 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$5.50 ➝ $5.50	+90.31%
6/28/2024	Rodman & Renshaw 1 of 5 stars	Initiated Coverage	Buy	$8.00	+351.98%
3/19/2024	Robert W. Baird 2 of 5 stars	Lower Target	Outperform ➝ Outperform	$11.00 ➝ $9.00	+320.56%
11/20/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$20.00 ➝ $12.00	+521.34%
11/14/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$18.50 ➝ $17.50	+1,106.89%
1/17/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$40.00 ➝ $30.00	+506.67%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:14 AM ET.

LPTX Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Leap Therapeutics is $7.50, with a high forecast of $9.00 and a low forecast of $5.50.
: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LPTX shares.
: According to analysts, Leap Therapeutics's stock has a predicted upside of 189.58% based on their 12-month stock forecasts.
: Leap Therapeutics has been rated by research analysts at HC Wainwright in the past 90 days.
: Analysts like Leap Therapeutics more than other "medical" companies. The consensus rating for Leap Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LPTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

This page (NASDAQ:LPTX) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Leap Therapeutics (LPTX) Stock Forecast & Price Target